Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
2011
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
2009
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
EglN2 associates with the NRF 1‐ PGC 1α complex and controls mitochondrial function in breast cancer
2015 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Les inhibiteurs de farnésyl transférase : une cible peut en cacher une autre
2003
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
2014
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
The molecular heterogeneity of protein kinase C and its implications for cellular regulation
1988 StandoutNature
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
2014
Functional RNA microarrays for high-throughput screening of antiprotein aptamers
2004
Aptamers—basic research, drug development, and clinical applications
2005
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin
2002
Compensatory Energetic Mechanisms Mediating the Assembly of Signaling Complexes Between Interleukin-2 and its α, β, and γc Receptors
2004
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
A Perspective on Dietary Phytochemicals and Cancer Chemoprevention: Oxidative Stress, Nrf2, and Epigenomics
2012
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Cancer stem cells revisited
2017 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
The Epigenomics of Cancer
2007 Standout
Epigenetics in Cancer
2008 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Iterative In Situ Click Chemistry Creates Antibody‐like Protein‐Capture Agents
2009 StandoutNobel
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
1998 Standout
Aptamers as therapeutics
2010 Standout
Molecular Biology of Vitamin D Action
1994
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Rolapitant: First Global Approval
2015
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Causes and consequences of microRNA dysregulation in cancer
2009 Standout
Aptamer Database
2003
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
2017 StandoutNobel
Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
2009
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
The CDK inhibitors in cancer research and therapy
2011
Epigenetic modifications as therapeutic targets
2010
Leukaemogenesis: more than mutant genes
2009
Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling
2017 StandoutNatureNobel
Therapy with azanucleosides for myelodysplastic syndromes
2010
Epigenetic modifications and human disease
2010 Standout
Developing a cancer‐specific geriatric assessment
2005
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Cancer and ageing: a nexus at several levels
2005
Total Synthesis of (18S)‐ and (18R)‐Homolargazole by Rhodium‐Catalyzed Hydrocarboxylation
2014
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Aptamers against extracellular targets for in vivo applications
2005
Biological effects of essential oils – A review
2007 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Histone Deacetylase Inhibitors as Anticancer Drugs
2017
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
Functional Nucleic Acid Sensors
2009 Standout
Immunochemical evidence that three protein kinase C isozymes increase in abundance during HL-60 differentiation induced by dimethyl sulfoxide and retinoic acid.
1988
Aptamer–Drug Conjugates
2015
Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study
2005
Differentiation therapy of leukemia: 3 decades of development
2009
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Nano-sized copper as an efficient catalyst for one pot three component synthesis of thiazolidine-2,4-dione derivatives
2008
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Transcriptional regulation of protein kinase C by 1,25-dihydroxyvitamin D3 in HL-60 cells.
1990
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
2010
Catalytic Asymmetric Hydroalkoxylation of C–C Multiple Bonds
2021 StandoutNobel
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
2007
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
2014
Four faces of cellular senescence
2011 Standout
Rational Combinations Using HDAC Inhibitors
2009
Comprehensive Geriatric Assessment for Older Patients With Cancer
2007
Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
2007
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Electrogenerated Chemiluminescence and Its Biorelated Applications
2008 Standout
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning
2012
Triggered amplification by hybridization chain reaction
2004 Standout
5-HT1A and histamine H1 receptors in HeLa cells stimulate phosphoinositide hydrolysis and phosphate uptake via distinct G protein pools.
1991 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Catalytic Asymmetric Protonation of Silyl Ketene Imines
2013 StandoutNobel
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
2010
Works of Robert E. Martell being referenced
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
2007
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
2011
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
2002
Optimizing Aptamer Activity for Gene Therapy Applications Using Expression Cassette SELEX
2002
Therapeutic Enhancement of IL-2 Through Molecular Design
2002
Reconstitution of DNA Synthetic Capacity in Senescent Normal Human Fibroblasts by Expressing Cellular Factors E2F and Mdm2
2001
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
2009
Comprehensive Assessment of the Elderly Cancer Patient: The Feasibility of Self-Report Methodology
2002
1,25-Dihydroxyvitamin D3 regulation of phorbol ester receptors in HL-60 leukemia cells.
1987
Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors
2006
Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).
2006
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
2014
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
2014
Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
2008
Diabetes, metformin use, and colorectal cancer survival in women: A retrospective cohort study.
2012
A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).
2005
Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors
2007
Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist.
2014
Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).
2007
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
2013
A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer
2005
Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
2007
Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay
2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
2008
Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
2008
Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011
2001
Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS)
2006
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
2014
Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
2008
Identification of lamin B and histones as 1,25-dihydroxyvitamin D3-regulated nuclear phosphoproteins in HL-60 cells.
1992